@article{f3b1d26db8f241ea9e1ff9f86a73f971,
title = "Vorapaxar in the secondary prevention of atherothrombotic events",
abstract = "Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1.",
keywords = "Aged, Brain Ischemia, Cardiovascular Diseases, Double-Blind Method, Female, Hemorrhage, Humans, Intracranial Hemorrhages, Kaplan-Meier Estimate, Lactones, Male, Middle Aged, Myocardial Infarction, Peripheral Arterial Disease, Platelet Aggregation Inhibitors, Pyridines, Receptor, PAR-1, Retreatment, Risk, Secondary Prevention, Stroke",
author = "Morrow, {David A} and Eugene Braunwald and Bonaca, {Marc P} and Ameriso, {Sebastian F} and Dalby, {Anthony J} and Fish, {Mary Polly} and Fox, {Keith A A} and Lipka, {Leslie J} and Xuan Liu and Nicolau, {Jos{\'e} Carlos} and Ophuis, {A J Oude} and Ernesto Paolasso and Scirica, {Benjamin M} and Jindrich Spinar and Pierre Theroux and Wiviott, {Stephen D} and John Strony and Murphy, {Sabina A} and {TRA 2P–TIMI 50 Steering Committee and Investigators} and Rasmussen, {Lars Hvilsted}",
year = "2012",
doi = "10.1056/NEJMoa1200933",
language = "English",
volume = "366",
pages = "1404--13",
journal = "The New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachusetts Medical Society",
}